Empirical Financial Services LLC d.b.a. Empirical Wealth Management Acquires New Holdings in Oruka Therapeutics, Inc. $ORKA

Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 15,406 shares of the company’s stock, valued at approximately $296,000.

Other institutional investors have also made changes to their positions in the company. Franklin Resources Inc. lifted its holdings in shares of Oruka Therapeutics by 40.6% in the 2nd quarter. Franklin Resources Inc. now owns 1,012,968 shares of the company’s stock worth $11,355,000 after acquiring an additional 292,421 shares during the last quarter. Geode Capital Management LLC increased its holdings in Oruka Therapeutics by 100.6% in the 2nd quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock valued at $7,932,000 after purchasing an additional 354,821 shares during the last quarter. Affinity Asset Advisors LLC raised its position in Oruka Therapeutics by 10.7% in the second quarter. Affinity Asset Advisors LLC now owns 603,479 shares of the company’s stock valued at $6,765,000 after purchasing an additional 58,117 shares during the period. Cable Car Capital LP raised its position in Oruka Therapeutics by 33.3% in the second quarter. Cable Car Capital LP now owns 600,000 shares of the company’s stock valued at $6,726,000 after purchasing an additional 150,000 shares during the period. Finally, Candriam S.C.A. lifted its stake in Oruka Therapeutics by 214.5% during the third quarter. Candriam S.C.A. now owns 366,994 shares of the company’s stock worth $7,057,000 after purchasing an additional 250,296 shares in the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ORKA. Jefferies Financial Group initiated coverage on Oruka Therapeutics in a research note on Thursday, November 13th. They issued a “buy” rating and a $45.00 price objective for the company. Piper Sandler began coverage on Oruka Therapeutics in a report on Thursday, December 18th. They set an “overweight” rating and a $75.00 target price for the company. Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, November 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Thursday, January 22nd. Finally, BTIG Research lifted their price objective on shares of Oruka Therapeutics from $63.00 to $73.00 and gave the company a “buy” rating in a report on Monday, January 12th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $54.50.

Insiders Place Their Bets

In related news, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $32.37, for a total value of $226,590.00. Following the completion of the transaction, the insider owned 34,018 shares in the company, valued at $1,101,162.66. The trade was a 17.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 21,000 shares of company stock valued at $663,530 over the last 90 days. 24.69% of the stock is owned by company insiders.

Oruka Therapeutics Price Performance

ORKA stock opened at $35.56 on Wednesday. The business’s 50-day moving average is $31.94 and its two-hundred day moving average is $25.89. The firm has a market capitalization of $1.72 billion, a P/E ratio of -18.72 and a beta of -0.38. Oruka Therapeutics, Inc. has a 1 year low of $5.49 and a 1 year high of $36.51.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.